{"id":748734,"date":"2025-06-23T17:22:01","date_gmt":"2025-06-23T17:22:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=748734"},"modified":"2025-06-23T17:22:01","modified_gmt":"2025-06-23T17:22:01","slug":"narcolepsy-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis-axsome-therapeutics-avadel-pharmaceuticals-suven","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/narcolepsy-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis-axsome-therapeutics-avadel-pharmaceuticals-suven_748734.html","title":{"rendered":"Narcolepsy Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Axsome Therapeutics, Avadel Pharmaceuticals, Suven"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/06\/1750659087.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Narcolepsy Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Axsome Therapeutics, Avadel Pharmaceuticals, Suven\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/06\/1750659087.jpg\" alt=\"Narcolepsy Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Axsome Therapeutics, Avadel Pharmaceuticals, Suven\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Narcolepsy Pipeline Insight, 2025<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cNarcolepsy &#8211; Pipeline Insight, 2025\u201d report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Narcolepsy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\">Narcolepsy Pipeline constitutes 15+ key companies continuously working towards developing 20+ Narcolepsy treatment therapies, analyzes DelveInsight.<\/p>\n<p style=\"text-align: justify;\"><strong>Narcolepsy Overview:<\/strong><\/p>\n<p style=\"text-align: justify;\">Narcolepsy is an uncommon, chronic neurological disorder characterized by the brain&#8217;s inability to properly control sleep-wake cycles, resulting in sudden and inappropriate sleep episodes. Key symptoms include persistent daytime drowsiness, difficulty staying alert, unexpected &#8220;sleep attacks,&#8221; cataplexy (a sudden, temporary loss of muscle tone often triggered by strong emotions), sleep paralysis (brief periods of immobility when falling asleep or waking up), and vivid dreams or disrupted nighttime sleep, including hypnagogic and hypnopompic hallucinations. The condition is often linked to a lack of hypocretin (also known as orexin), a brain chemical that helps maintain wakefulness. Although narcolepsy is rare and frequently underdiagnosed&mdash;making prevalence estimates challenging&mdash;symptom management is possible through lifestyle adjustments and medications, even though there is currently no cure.<\/p>\n<p style=\"text-align: justify;\">&#8220;Narcolepsy Pipeline Insight 2025&#8221; report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Narcolepsy Therapeutics Market.<\/p>\n<p style=\"text-align: justify;\"><strong>Download narcolepsy pipeline insights report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/narcolepsy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/report-store\/narcolepsy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Narcolepsy Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>DelveInsight&rsquo;s Narcolepsy pipeline report highlights a dynamic landscape, with over 15 active companies developing more than 20 pipeline therapies aimed at treating the condition.<\/p>\n<\/li>\n<li>\n<p>In September 2025, Takeda is set to share new clinical trial data on its Orexin Agonist TAK-861, focusing on its impact on narcolepsy, at the Sleep Europe 2025 conference.<\/p>\n<\/li>\n<li>\n<p>Leading players in this space include Axsome Therapeutics, Avadel Pharmaceuticals, Suven Life Sciences, Takeda, NLS Pharmaceutics, Vallon Pharmaceuticals, Alkermes, Centessa Pharmaceuticals, Ono Pharma, Harmony Biosciences, Reset Therapeutics, XWPharma, Sunovion Pharmaceuticals, Otsuka Pharmaceutical, ConSynance Therapeutics, KemPharm, and others.<\/p>\n<\/li>\n<li>\n<p>Prominent therapies currently in development include FT218, AXS-12, among others, showing promise in enhancing the narcolepsy treatment landscape.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Narcolepsy Pipeline Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\">The report provides insights into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The report provides detailed insights into the key companies that are developing therapies in the Narcolepsy Market.<\/p>\n<\/li>\n<li>\n<p>The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Narcolepsy treatment.<\/p>\n<\/li>\n<li>\n<p>It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li>\n<p>It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/p>\n<\/li>\n<li>\n<p>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Narcolepsy market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Download our free narcolepsy sample report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/narcolepsy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/sample-request\/narcolepsy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">Narcolepsy Emerging Drugs<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>FT218: Avadel Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p>AXS-12: Axsome therapeutics<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Narcolepsy Companies<\/strong><\/p>\n<p style=\"text-align: justify;\">Over 15 leading companies are actively developing treatments for narcolepsy. Among these, Avadel Pharmaceuticals has the most advanced drug candidates, with one therapy currently in the preregistration phase.<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s report covers around 22+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Late stage products (Phase III)<\/p>\n<\/li>\n<li>\n<p>Mid-stage products (Phase II)<\/p>\n<\/li>\n<li>\n<p>Early-stage product (Phase I) along with the details of<\/p>\n<\/li>\n<li>\n<p>Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li>\n<p>Discontinued &amp; Inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Narcolepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Intravenous<\/p>\n<\/li>\n<li>\n<p>Subcutaneous<\/p>\n<\/li>\n<li>\n<p>Oral<\/p>\n<\/li>\n<li>\n<p>Intramuscular<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Narcolepsy Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Monoclonal antibody<\/p>\n<\/li>\n<li>\n<p>Small molecule<\/p>\n<\/li>\n<li>\n<p>Peptide<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Download Sample Pages to Get an in-depth Assessment of the Emerging Narcolepsy Therapies and Key Companies: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/narcolepsy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Narcolepsy Clinical Trials and advancements<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">Narcolepsy Pipeline Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">&bull; Narcolepsy Assessment by Product Type<\/p>\n<p style=\"text-align: justify;\">&bull; Narcolepsy By Stage<\/p>\n<p style=\"text-align: justify;\">&bull; Narcolepsy Assessment by Route of Administration<\/p>\n<p style=\"text-align: justify;\">&bull; Narcolepsy Assessment by Molecule Type<\/p>\n<p style=\"text-align: justify;\"><strong>Download Narcolepsy Sample report to know in detail about the Narcolepsy treatment market @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/narcolepsy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Narcolepsy Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Narcolepsy Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">4. Narcolepsy &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6. Narcolepsy Late-Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. Narcolepsy Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Narcolepsy Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. Narcolepsy Product Profiles<\/p>\n<p style=\"text-align: justify;\">14. Narcolepsy Key Companies<\/p>\n<p style=\"text-align: justify;\">15. Narcolepsy Key Products<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">17. Narcolepsy Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Narcolepsy Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Narcolepsy Analyst Review<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><strong>Request the Sample PDF to Get Detailed Insights About the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/narcolepsy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Narcolepsy Pipeline Reports Offerings<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=narcolepsy-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis-axsome-therapeutics-avadel-pharmaceuticals-suven\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=narcolepsy-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis-axsome-therapeutics-avadel-pharmaceuticals-suven\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Narcolepsy Pipeline Insight, 2025 DelveInsight\u2019s, \u201cNarcolepsy &#8211; Pipeline Insight, 2025\u201d report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Narcolepsy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/narcolepsy-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis-axsome-therapeutics-avadel-pharmaceuticals-suven_748734.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-748734","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/748734","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=748734"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/748734\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=748734"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=748734"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=748734"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}